Comparing the effects of decreasing prescription opioid shipments and the release of an abuse deterrent OxyContin formulation on opioid overdose fatalities in WV: an interrupted time series study
Open Access
- 4 January 2024
- journal article
- research article
- Published by Springer Nature in Substance Abuse Treatment, Prevention, and Policy
- Vol. 19 (1) , 1-13
Abstract
The 2010 release of an abuse deterrent formulation (ADF) of OxyContin, a brand name prescription opioid, has been cited as a major driver for the reduction in prescription drug misuse and the associated increasing illicit opioid use and overdose rates. However, studies of this topic often do not account for changes in supplies of other prescription opioids that were widely prescribed before and after the ADF OxyContin release, including generic oxycodone formulations and hydrocodone. We therefore sought to compare the impact of the ADF OxyContin release to that of decreasing prescription opioid supplies in West Virginia (WV). Opioid tablet shipment and overdose data were extracted from The Washington Post ARCOS (2006–2014) and the WV Forensic Drug Database (2005–2020), respectively. Locally estimated scatterplot smoothing (LOESS) was used to estimate the point when shipments of prescription opioids to WV began decreasing, measured via dosage units and morphine milligram equivalents (MMEs). Interrupted time series analysis (ITSA) was used to compare the impact LOESS-identified prescription supply changes and the ADF OxyContin release had on prescription (oxycodone and hydrocodone) and illicit (heroin, fentanyl, and fentanyl analogues) opioid overdose deaths in WV. Model fit was compared using Akaike Information Criteria (AIC). The majority of opioid tablets shipped to WV from 2006 to 2014 were generic oxycodone or hydrocodone, not OxyContin. After accounting for a 6-month lag from ITSA models using the LOESS-identified change in prescription opioid shipments measured via dosage units (2011 Q3) resulted in the lowest AIC for both prescription (AIC = -188.6) and illicit opioid-involved overdoses (AIC = -189.4), indicating this intervention start date resulted in the preferred model. The second lowest AIC was for models using the ADF OxyContin release as an intervention start date. We found that illicit opioid overdoses in WV began increasing closer to when prescription opioid shipments to the state began decreasing, not when the ADF OxyContin release occurred. Similarly, the majority of opioid tablets shipped to the state for 2006–2014 were generic oxycodone or hydrocodone. This may indicate that diminishing prescription supplies had a larger impact on opioid overdose patterns than the ADF OxyContin release in WV.Keywords
Funding Information
- US National Institute of General Medical Sciences (U54GM104942, U54GM104942)
This publication has 44 references indexed in Scilit:
- Changes in Prevalence of Prescription Opioid Abuse after Introduction of an Abuse-Deterrent Opioid FormulationPain Medicine, 2014
- Use of Interrupted Time Series Analysis in Evaluating Health Care Quality ImprovementsAcademic Pediatrics, 2013
- Changes in oxycodone and heroin exposures in the National Poison Data System after introduction of extended‐release oxycodone with abuse‐deterrent characteristicsPharmacoepidemiology and Drug Safety, 2013
- The effect of the late 2000s financial crisis on suicides in Spain: an interrupted time-series analysisEuropean Journal of Public Health, 2013
- Effect of Abuse-Deterrent Formulation of OxyContinNew England Journal of Medicine, 2012
- The Promotion and Marketing of OxyContin: Commercial Triumph, Public Health TragedyAmerican Journal of Public Health, 2009
- Relationship between therapeutic use and abuse of opioid analgesics in rural, suburban, and urban locations in the United StatesPharmacoepidemiology and Drug Safety, 2007
- Trends in Abuse of OxyContin® and Other Opioid Analgesics in the United States: 2002-2004The Journal of Pain, 2005
- Loess:Electoral Studies, 2000
- On a measure of lack of fit in time series modelsBiometrika, 1978